Table 3.
In vitro bioactivity of EGFR-specific Db-scTRAIL variants with or without EGFR blocking by cetuximab, in presence of bortezomib (mean ± SD, n = 3).
| EC50 (pM) |
||||
|---|---|---|---|---|
| Molecule | Cetuximab | Colo205 | HT1080 | HCT116 |
| Db-scTRAIL-95L8 | − | 24 ± 4 | 3 ± 0.7 | 127 ± 2 |
| + | 48 ± 5 | 15 ± 4 | 381 ± 16 | |
| Db-Glyco-scTRAIL-FAVSGAA | − | 33 ± 6 | 1 ± 0.6 | 66 ± 10 |
| + | 74 ± 15 | 10 ± 4 | 450 ± 2 | |
| Db10-Glyco-scTRAIL-FAVSGAA | − | 13 ± 2 | 0.7 ± 0.2 | 39 ± 4 |
| + | 66 ± 17 | 8 ± 2 | 298 ± 3 | |
| Db-Glyco-scTRAIL-FAVSGIA | − | 19 ± 3 | 0.6 ± 0.2 | 43 ± 2 |
| + | 32 ± 5 | 5 ± 1 | 161 ± 3 | |